An experimental cancer vaccine in early-stage development at the University of California San Francisco has sparked hope that patients with acute myeloid leukemia (AML), an aggressive cancer of the blood, could one day have a life-saving alternative, especially those prone to relapse or unable to ...

Thea D. Tlsty, PhD, Professor of Pathology and a UCSF leader in cell cycling and signaling, received a $26 million Grand Challenge Grant from Cancer Research UK (CRUK) to lead an international team exploring how chronic inflammation causes cancer. 

Regular use of a common type of medication, such as aspirin and ibuprofen, significantly improves survival for a third or more patients with head and neck cancer, a new study led by UC San Francisco has found.  Non-steroidal anti-inflammatory drugs, or NSAIDs, improved the overall ...

In laboratory experiments, UC San Francisco researchers successfully beat back the growth of aggressive liver cancers using a surprising new approach. Traditionally, targeted cancer therapies aim to disable proteins borne of cancer-driving genes. Instead, the UCSF scientists prevented these proteins, including those that shield tumors ...

Using a divide and conquer strategy, researchers from the University of California San Francisco have provided a road map for the development of a precision medicine approach to osteosarcoma, the most common bone cancer in children and young adults and an aggressive disease for ...